摘要
目的探讨慢性阻塞性肺疾病(COPD)患者应用布地奈德、硫酸特布他林联合乙酰半胱氨酸雾化吸入治疗的临床效果。方法选取2020年1月至2022年12月龙南市第一人民医院收治的COPD患者60例作为研究对象,采用随机数字表法分为对照组(n=30,布地奈德联合硫酸特布他林)和观察组(n=30,对照组基础上加用乙酰半胱氨酸治疗)。比较两组临床疗效,治疗前后肺功能指标[第一秒钟用力呼气容积(FEV_(1))、用力肺活量(FVC)以及第一秒钟用力呼气容积占用力肺活量百分比(FEV_(1)/FVC)]及氧化应激反应指标[超氧化物歧化酶(SOD)、丙二醛(MDA)],治疗前后6 min步行试验(6-MWT)、呼吸困难症状[改良呼吸困难指数(mMRC)评分]及生命质量[日常生活活动能力量表(ADL)评分]变化。结果观察组治疗有效率为93.33%,高于对照组的73.33%(P<0.05)。治疗后,两组FVC、FEV_(1)及FEV_(1)/FVC均较治疗前升高(P<0.05),且观察组各指标均高于对照组(P<0.05)。治疗后,两组SOD水平均较治疗前升高(P<0.05),MDA水平较治疗前降低(P<0.05),且观察组SOD水平高于对照组(P<0.05),MDA水平低于对照组(P<0.05)。治疗后,两组6-MWT、ADL评分均较治疗前升高(P<0.05),mMRC评分较治疗前降低(P<0.05),且观察组6-MWT、ADL评分均高于对照组(P<0.05),mMRC评分低于对照组(P<0.05)。结论COPD采用布地奈德、硫酸特布他林、乙酰半胱氨酸联合雾化吸入治疗疗效显著,可改善患者肺功能及呼吸困难症状,减轻氧化应激反应,提高生命质量。
Objective To explore the clinical effect of budesonide,terbutaline sulfate combined with acetylcysteine in the treatment of chronic obstructive pulmonary disease(COPD).Methods 60 patients with COPD admitted to the First People's Hospital from January 2020 to December 2022 were included and divided into control group(n=30,budesonide combined with terbutaline)and observation group(n=30,control group was added with acetylcysteine)according to random number table method.The clinical efficacy,and the lung function[forced expiratory volume in the first second(FEV_(1)),forced vital capacity(FVC),the percentage of forced expiratory volume in the first second(FEV_(1)/FVC)]and the oxidative stress response[superoxide dismutase(SOD),malondialdehyde(MDA)]of the two groups before and after treatment were observed.The changes of 6-min walking test(6-MWT),dyspnea symptoms[modified dyspnea Index(mMRC)score]and quality of life[Ability of Daily Living Scale(ADL)score]before and after treatment were compared between the two groups.Results The effective rate of the observation group was 93.33%,which was higher than that of the control group(73.33%)(P<0.05).After treatment,FVC,FEV_(1) and FEV_(1)/FVC in both groups were higher than those before treatment(P<0.05),and the indexes in the observation group were higher than those in the control group(P<0.05).After treatment,SOD level in both groups was higher than before treatment(P<0.05),MDA level was lower than before treatment(P<0.05),and SOD level in observation group was higher than that in control group(P<0.05),MDA level was lower than that in control group(P<0.05).After treatment,6-MWT and ADL scores in both groups were higher than before treatment(P<0.05),and mMRC scores were lower than before treatment(P<0.05),and 6-MWT and ADL scores in observation group were higher than those in control group(P<0.05),and mMRC scores were lower than those in control group(P<0.05).Conclusion The combination of budesonide,terbutaline sulfate and acetylcysteine in the treatment of COPD has signific
作者
廖胜杰
LIAO Sheng-Jie(Department of Respiratory Oncology,The First People's Hospital of Longnan City,Ganzhou 341700,China)
出处
《中国药物经济学》
2023年第11期62-65,69,共5页
China Journal of Pharmaceutical Economics
